Biocryst Pharmaceuticals(BCRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BCRX Biocryst Pharmaceuticals

Trading 10-30 10:04:58 EDT

8.50

-0.02

-0.29%

High8.62	Low8.49	Vol193.41K
Open8.55	D1 Closing8.52	Amplitude1.55%
Mkt Cap2.17B	Tradable Cap1.89B	Total Shares255.54M
T/O1.65M	T/O Rate0.09%	Tradable Shares222.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BCRX","market":"US","secType":"STK","nameCN":"Biocryst Pharmaceuticals","latestPrice":8.495,"timestamp":1793369096768,"preClose":8.52,"halted":0,"volume":193412,"delay":0,"changeRate":-0.0029342723004695255,"floatShares":222000000,"shares":255535105,"eps":-1.5053626,"marketStatus":"Trading","change":-0.025,"latestTime":"10-30 10:04:58 EDT","open":8.55,"high":8.6172,"low":8.485,"amount":1651951.426612,"amplitude":0.015516,"askPrice":8.5,"askSize":300,"bidPrice":8.49,"bidSize":1070,"shortable":3,"etf":0,"ttmEps":-1.5053626,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1793390400000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":762670800000,"exchange":"NASDAQ","adjPreClose":8.52,"preHourTrading":{"tag":"盘前","latestPrice":8.58,"preClose":8.52,"latestTime":"09:20 EDT","volume":4204,"amount":35917.328032000005,"timestamp":1793366441689,"change":0.06,"changeRate":0.007042,"amplitude":0.066573},"postHourTrading":{"tag":"盘后","latestPrice":8.49,"preClose":8.52,"latestTime":"19:51 EDT","volume":1283469,"amount":10934992.5081,"timestamp":1793317902055,"change":-0.03,"changeRate":-0.003521,"amplitude":0.032394},"volumeRatio":0.442788,"impliedVol":0.5286,"impliedVolPercentile":0.255},"requestUrl":"/m/hq/s/BCRX/tweets","defaultTab":"tweets","newsList":[{"id":"1172757304","title":"Earning Preview: Biocryst Pharmaceuticals this quarter’s revenue is expected to increase by 1.66%, and institutional views are largely positive","url":"https://stock-news.laohu8.com/highlight/detail?id=1172757304","media":"Earnings Agent","labels":["earningPreview"],"top":1,"itemType":null,"share":"https://ttm.financial/m/news/1172757304?lang=en_us&edition=fundamental","pubTime":"2026-10-29 00:05","pubTimestamp":1793203502,"startTime":"0","endTime":"0","summary":"Abstract Biocryst Pharmaceuticals will report third-quarter 2026 financial results on November 4, 2026, Pre-Mkt; this preview compiles consensus forecasts, last quarter’s scorecard, and the key watch...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Earning Preview: Biocryst Pharmaceuticals this quarter’s revenue is expected to increase by 1.66%, and institutional views are largely positive","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679405634","title":"BioCryst to Present New Orladeyo Clinical Data at ACAAI Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2679405634","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2679405634?lang=en_us&edition=fundamental","pubTime":"2026-10-29 19:19","pubTimestamp":1793272777,"startTime":"0","endTime":"0","summary":"BioCryst to Present New ORLADEYO Clinical Data at ACAAI MeetingBioCryst will present four hereditary angioedema abstracts at the ACAAI annual scientific meeting in Phoenix, Nov. 12-16, 2026.ORLADEYO p","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261029:nNDL93sKkY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","BK4588","NDAQ","IE00B64PRP62.GBP","IE00BN0W2V16.EUR","SG9999014039.USD","BK4112","BCRX","LU2095319765.USD","LU2210149790.SGD","IE00BQXX3F31.USD","BK4139","IE00B3QW5Z07.USD","IE00BKPKM429.USD","IE00BQXX3C00.GBP","BCDF","IE00BGHQF748.EUR","SG9999014021.USD","BK4547","SG9999014013.SGD","BK4585","LU2210150020.SGD","IE00BN0W2T93.GBP","IE00BQXX3D17.EUR","LU0314104364.USD","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677604337","title":"BioCryst to Report Third-Quarter Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2677604337","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677604337?lang=en_us&edition=fundamental","pubTime":"2026-10-22 04:01","pubTimestamp":1792612883,"startTime":"0","endTime":"0","summary":"BioCryst to Report Third-Quarter Financial ResultsBioCryst Pharmaceuticals will report third-quarter 2026 financial results on Nov. 4, 2026.Management will host a conference call and webcast on Nov. 4","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261021:nNDL1ZMV2c:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","SG9999014021.USD","IE00BKPKM429.USD","BK4588","BK4139","BCRX","LU2210149790.SGD","NDAQ","IE00BN0W2T93.GBP","BK4112","BCDF","IE00BGHQF748.EUR","LU0314104364.USD","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","LU2095319765.USD","IE00B64PRP62.GBP","SG9999014013.SGD","IE00BQXX3F31.USD","IE00BQXX3C00.GBP","BK4585","LU2210150020.SGD","SG9999014039.USD","BK4547","SG9999014005.SGD","IE00BQXX3D17.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677671283","title":"BioCryst Pharmaceuticals Pellet Form of Hereditary Angioedema Treatment Approved by US FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2677671283","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677671283?lang=en_us&edition=fundamental","pubTime":"2026-10-21 20:48","pubTimestamp":1792586935,"startTime":"0","endTime":"0","summary":"BioCryst Pharmaceuticals  supplemental new drug application for the oral pellet formulation of once-daily Orladeyo as a prophylactic therapy for hereditary angioedema has been approved by the US Food and Drug Administration, the company said Wednesday.The 150 milligram pellet formulation which can be poured directly into the month is meant for adults and adolescents aged 12 or older, the company said.In two clinical studies, the capsules reduced sustained attacks in patients by 91% at 96 weeks, the company said.Shares of the company were up 1.8% in recent premarket trading.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BCRX","BK4547","BK4588","LABU","BK4139","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677678017","title":"BioCryst Announces U.S. FDA Approval of Orladeyo® 150 Mg Oral Pellets for Adults and Adolescents with Hae","url":"https://stock-news.laohu8.com/highlight/detail?id=2677678017","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677678017?lang=en_us&edition=fundamental","pubTime":"2026-10-21 19:00","pubTimestamp":1792580405,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261021:nTUA1RFNZ2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BCRX","BK4139","BK4547"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676688361","title":"Wedbush Cuts Price Target on BioCryst Pharmaceuticals to $18 From $20, Keeps Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2676688361","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676688361?lang=en_us&edition=fundamental","pubTime":"2026-10-19 19:11","pubTimestamp":1792408292,"startTime":"0","endTime":"0","summary":"BioCryst Pharmaceuticals (BCRX) has an average rating of buy and mean price target of $20.73, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4547","BCRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675657803","title":"How New Advisory Board At BioCryst Pharmaceuticals (BCRX) Has Changed Its Investment Story","url":"https://stock-news.laohu8.com/highlight/detail?id=2675657803","media":"Simply Wall St.","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675657803?lang=en_us&edition=fundamental","pubTime":"2026-10-13 23:30","pubTimestamp":1791905444,"startTime":"0","endTime":"0","summary":"BioCryst Pharmaceuticals recently formed a seven-member Scientific Advisory Board made up of senior figures in rare disease research, drug development, and clinical strategy to guide pipeline expansion, translational science, and regulatory planning.\nThe group’s experience building rare disease portfolios, advancing first-in-class therapies, and advising on AI and translational platforms gives BioCryst Pharmaceuticals access to high-level operational insight that could influence future R&D...","market":"sg","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bcrx/biocryst-pharmaceuticals/news/how-new-advisory-board-at-biocryst-pharmaceuticals-bcrx-has","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bcrx/biocryst-pharmaceuticals/news/how-new-advisory-board-at-biocryst-pharmaceuticals-bcrx-has","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4547","BCRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673707633","title":"BioCryst Pharmaceuticals Forms Scientific Advisory Board as R&D Model Evolves","url":"https://stock-news.laohu8.com/highlight/detail?id=2673707633","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673707633?lang=en_us&edition=fundamental","pubTime":"2026-10-05 20:33","pubTimestamp":1791203630,"startTime":"0","endTime":"0","summary":"BioCryst Pharmaceuticals  formed a seven-member Scientific Advisory Board to guide its research & development strategy and help expand its rare disease pipeline, the company said Monday.The board will advise on pipeline expansion, external innovation opportunities, translational science, clinical development and regulatory strategy, the company said.BioCryst Pharmaceuticals shares were up 1.4% in premarket activity.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BCRX","BK4139","BK4547"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673048887","title":"BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2673048887","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673048887?lang=en_us&edition=fundamental","pubTime":"2026-10-05 19:00","pubTimestamp":1791198001,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nTUA4WB8ZF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BCRX","BK4547","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671279309","title":"US Research Roundup-Alnylam Pharmaceuticals, Carvana, MongoDB","url":"https://stock-news.laohu8.com/highlight/detail?id=2671279309","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671279309?lang=en_us&edition=fundamental","pubTime":"2026-09-30 15:35","pubTimestamp":1790753728,"startTime":"0","endTime":"0","summary":"US RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDBSept 30 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several US-listed companies, including Alnylam","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nL4N45M0G7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SKYY","ACHV","MDB","IOND","AEE","HNGE","LITE","EMN","HAWK","KMX","AJG","CE","MRSH","MRNA","CC","CSCS","LW","ANNX","HUN","CSCL","GSHD","GPK","JAZZ","DOW","MRNX","CSCO","COHR","ALNY","GLW","IMMX","MSFD","EGGY","BCRX","CIEN","FSLR","BBUC","BRO","ANET","SPRX","ANAB","AIR","MSFT","AMPL","GNRC","CVNA","GAMR","MSFO","DYN","CCL","EFIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671222896","title":"BioCryst Pharmaceuticals, Inc. : JP Morgan Raises Target Price to $13 from $12","url":"https://stock-news.laohu8.com/highlight/detail?id=2671222896","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671222896?lang=en_us&edition=fundamental","pubTime":"2026-09-30 11:21","pubTimestamp":1790738514,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nFWN45L1NF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4547","BCRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669468356","title":"Will Japan Pediatric Approval Change BioCryst Pharmaceuticals (BCRX) Narrative","url":"https://stock-news.laohu8.com/highlight/detail?id=2669468356","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669468356?lang=en_us&edition=fundamental","pubTime":"2026-09-24 13:27","pubTimestamp":1790227647,"startTime":"0","endTime":"0","summary":"BioCryst Pharmaceuticals received approval from Japan's Ministry of Health for once daily ORLADEYO to treat children aged 2 to 12 with hereditary angioedema, creating the first oral prophylactic option for pediatric HAE patients in that market and extending the drug's pediatric label internationally.\nThis expanded pediatric use gives BioCryst Pharmaceuticals a broader treated population for its lead product, which can help absorb fixed commercial costs and support the shift toward an...","market":"hk","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bcrx/biocryst-pharmaceuticals/news/will-japan-pediatric-approval-change-biocryst-pharmaceutical","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bcrx/biocryst-pharmaceuticals/news/will-japan-pediatric-approval-change-biocryst-pharmaceutical","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","BK4547","BCRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669125626","title":"GlycoEra Names Andrea Matthews Chief Business Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2669125626","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669125626?lang=en_us&edition=fundamental","pubTime":"2026-09-23 00:05","pubTimestamp":1790093159,"startTime":"0","endTime":"0","summary":"GlycoEra names Andrea Matthews chief business officerLifeArc Ventures-backed GlycoEra named Andrea Matthews chief business officer to support its next phase of growth.Matthews was chief business offic","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nNDLcfK3j6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4547","BCRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666925855","title":"BioCryst Pharmaceuticals Faces Competitive Pressure in Hereditary Angioedema Treatment, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2666925855","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666925855?lang=en_us&edition=fundamental","pubTime":"2026-09-10 23:42","pubTimestamp":1789054974,"startTime":"0","endTime":"0","summary":"BioCryst Pharmaceuticals'  Ordaleyo faces competitive pressure in the hereditary angioedema treatment space, and its shares are expected to settle within an in-line trading range in the near term, RBC Capital Markets said in a Thursday note.Pharvaris'  released stronger-than-expected data for deucrictibant XR, its competing oral agent for treating hereditary angioedema, and conversations with key opinion leaders revealed that more doctors may move patients from Ordaleyo to the rival offering than consensus numbers would imply, RBC analysts said.The analysts said they see Ordaleyo likely continuing to grow in the near term, but now project Ordaleyo's long-term annual revenue to drop to a range of $400 million to $450 million from their previous estimate of $500 million to $550 million.Meanwhile, the analysts said they are optimistic that BioCryst's long-acting injectable navenibart will drive a new phase of growth, clinical data is likely still a year away, and the launch of deucrictiba","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","BK4547","BCRX","PHVS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666956202","title":"RBC Downgrades BioCryst Pharmaceuticals to Sector Perform From Outperform, Cuts Price Target to $11 From $13","url":"https://stock-news.laohu8.com/highlight/detail?id=2666956202","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666956202?lang=en_us&edition=fundamental","pubTime":"2026-09-10 18:30","pubTimestamp":1789036238,"startTime":"0","endTime":"0","summary":"BioCryst Pharmaceuticals (BCRX) has an average rating of buy and mean price target of $20.64, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK4547","BCRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666198561","title":"BioCryst Pharmaceuticals, Inc. : RBC Cuts to Sector Perform from Outperform; Cuts Target Price to $11 from $13","url":"https://stock-news.laohu8.com/highlight/detail?id=2666198561","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666198561?lang=en_us&edition=fundamental","pubTime":"2026-09-10 17:34","pubTimestamp":1789032847,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nFWN452092:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4547","BCRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666636615","title":"U.S. Research Roundup-Caseys General Stores, Targa Resources, United Rentals","url":"https://stock-news.laohu8.com/highlight/detail?id=2666636615","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666636615?lang=en_us&edition=fundamental","pubTime":"2026-09-10 15:23","pubTimestamp":1789024986,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Caseys General Stores, Targa Resources, United RentalsSept 10 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nL4N4520I0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABNB","AEO","CASY","CHRD","ILDR","COIN","AVAV","EOG","EAT","XYZ","AR","DAL","CLDX","ET","AMD","IEZ","AAPL","AAL","COIA","CLOV","COP","DRLL","MASS","BBOT","BCRX","BG","APA","EQT","AVGW","AVGO","AWK","AEHR","PXJ","AZO","AU","DVN","TRFK","ASO","FANG","COIO","BKR","AMDL","ABVX","CNM","CRC","HP","ALK","CON","CPG.UK","DPZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666746293","title":"BioCryst Pharmaceuticals Price Target Maintained with a $16.00/Share by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2666746293","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666746293?lang=en_us&edition=fundamental","pubTime":"2026-09-09 01:42","pubTimestamp":1788889320,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BCRX/analyst-ratings","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4547","BCRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666374637","title":"Analysts’ Top Healthcare Picks: Spyre Therapeutics (SYRE), BioCryst (BCRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2666374637","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666374637?lang=en_us&edition=fundamental","pubTime":"2026-09-09 01:20","pubTimestamp":1788888012,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Spyre Therapeutics (SYRE) and BioCryst (BCRX) with b...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-spyre-therapeutics-syre-biocryst-bcrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-spyre-therapeutics-syre-biocryst-bcrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4547","LABU","BK4137","BK4585","BK4581","XBI","XLV","LU0128526141.USD","SYRE","BCRX","HCSG","LU0029874061.USD","BK4139","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662739474","title":"BioCryst announces Japan MHLW marketing approval for Orladeyo","url":"https://stock-news.laohu8.com/highlight/detail?id=2662739474","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662739474?lang=en_us&edition=fundamental","pubTime":"2026-08-25 19:15","pubTimestamp":1787656520,"startTime":"0","endTime":"0","summary":"BioCryst (BCRX) announced that Japan’s Ministry of Health, Labor and Welfare has granted marketing approval for once-daily Orladeyo for prophylacti...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/biocryst-announces-japan-mhlw-marketing-approval-for-orladeyo-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/biocryst-announces-japan-mhlw-marketing-approval-for-orladeyo-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4547","BCRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.biocryst.com","stockEarnings":[{"period":"1week","weight":0.0951},{"period":"1month","weight":0.0302},{"period":"3month","weight":-0.0512},{"period":"6month","weight":-0.0729},{"period":"1year","weight":0.1655},{"period":"ytd","weight":0.0923}],"compareEarnings":[{"period":"1week","weight":0.0071},{"period":"1month","weight":0.0068},{"period":"3month","weight":0.0299},{"period":"6month","weight":0.0676},{"period":"1year","weight":0.1192},{"period":"ytd","weight":0.1282}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor for complement-mediated diseases; and Galidesivir, to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.","yearOnYearQuotes":[{"month":1,"riseRate":0.5625,"avgChangeRate":0.02531},{"month":2,"riseRate":0.53125,"avgChangeRate":-0.000169},{"month":3,"riseRate":0.375,"avgChangeRate":0.017253},{"month":4,"riseRate":0.545455,"avgChangeRate":0.046266},{"month":5,"riseRate":0.545455,"avgChangeRate":0.060211},{"month":6,"riseRate":0.606061,"avgChangeRate":0.030077},{"month":7,"riseRate":0.545455,"avgChangeRate":0.106685},{"month":8,"riseRate":0.606061,"avgChangeRate":0.099081},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.052273},{"month":10,"riseRate":0.515152,"avgChangeRate":-0.044841},{"month":11,"riseRate":0.46875,"avgChangeRate":0.037572},{"month":12,"riseRate":0.5,"avgChangeRate":0.004698}],"exchange":"NASDAQ","name":"Biocryst Pharmaceuticals","nameEN":"Biocryst Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.1","shortVersion":"4.52.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Biocryst Pharmaceuticals(BCRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Biocryst Pharmaceuticals(BCRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Biocryst Pharmaceuticals,BCRX,Biocryst Pharmaceuticals股票,Biocryst Pharmaceuticals股票老虎,Biocryst Pharmaceuticals股票老虎国际,Biocryst Pharmaceuticals行情,Biocryst Pharmaceuticals股票行情,Biocryst Pharmaceuticals股价,Biocryst Pharmaceuticals股市,Biocryst Pharmaceuticals股票价格,Biocryst Pharmaceuticals股票交易,Biocryst Pharmaceuticals股票购买,Biocryst Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Biocryst Pharmaceuticals(BCRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Biocryst Pharmaceuticals(BCRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction